Author

Saritha Muppa

Institution: BioCryst Pharmaceuticals (United States)

Observed institutions: Iowa State University, BioCryst Pharmaceuticals (United States)

ORCID: 0009-0007-6362-3415

Observed ORCID: 0009-0007-6362-3415

OpenAlex ID: A5029949840

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

2021 · Pravin L Kotian, Minwan Wu, et al. · Journal of Medicinal Chemistry · 36

Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors

2022 · Weihe Zhang, Minwan Wu, et al. · Bioorganic & Medicinal Chemistry · 6

Discovery and optimization of orally bioavailable and potent plasma Kallikrein inhibitors bearing a quaternary carbon

2022 · Weihe Zhang, Satish Vadlakonda, et al. · Bioorganic & Medicinal Chemistry · 3

Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH)

2020 · Xilin Chen, Xiaogang Cheng, et al. · Blood · 3

BCX9250 is a potent small-molecule inhibitor of Activin A Receptor Type 1 (ACVR1/ALK2) for fibrodysplasia ossificans progressiva

2026 · Haitao Wang, Saman Toutounchi, et al. · JBMR Plus

Molecular detection of pathogenic Fusarium species in roots and stalks of maize plants with or without transgenic resistance to corn rootworm

2009 · Saritha Muppa · Iowa State University Digital Repository (Iowa State University)

Works count: 6

Citation count: 48

H-index: 3

I10-index: 1